Indirect

10568380c.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAY 01	New CAS web site launched
NEWS 3	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 4	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 5	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 6	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 7	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 8	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 9	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 10	JUN 29	STN Viewer now available
NEWS 11	JUN 29	STN Express, Version 8.2, now available
NEWS 12	JUL 02	LEMBASE coverage updated
NEWS 13	JUL 02	LMEDLINE coverage updated
NEWS 14	JUL 02	SCISEARCH enhanced with complete author names
NEWS 15	JUL 02	CHEMCATS accession numbers revised
NEWS 16	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 17	JUL 16	CAplus enhanced with French and German abstracts
NEWS 18	JUL 18	CA/CAplus patent coverage enhanced
NEWS 19	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 20	JUL 30	USGENE now available on STN
NEWS 21	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 22	AUG 06	BEILSTEIN updated with new compounds
NEWS 23	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 24	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:22:21 ON 15 AUG 2007

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:22:41 ON 15 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 AUG 2007 HIGHEST RN 944643-48-5
DICTIONARY FILE UPDATES: 14 AUG 2007 HIGHEST RN 944643-48-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10568380c.str



chain nodes :
12 13 14 15 16 17 18 19 20 22 24 25 26
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
2-10 4-16 5-12 12-13 12-19 13-14 13-15 14-20 14-24 16-17 16-18 17-25
17-26
ring bonds :
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11
exact/norm bonds :
5-12 12-13 13-14 13-15 16-17 16-18 17-26
exact bonds :
1-2 1-5 2-3 2-10 3-4 4-5 4-16 12-19 14-20 14-24 17-25
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11
isolated ring systems :
containing 1 : 6 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 22:CLASS 23:Atom 24:CLASS 25:CLASS 26:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 09:22:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       43 TO ITERATE

100.0% PROCESSED       43 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          467 TO     1253
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 09:23:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1034 TO ITERATE

100.0% PROCESSED     1034 ITERATIONS                              94 ANSWERS
SEARCH TIME: 00.00.01

L3           94 SEA SSS FUL L1

=> FIL HCAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   172.10     172.31

FILE 'HCAPLUS' ENTERED AT 09:23:12 ON 15 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Aug 2007 VOL 147 ISS 8
FILE LAST UPDATED: 14 Aug 2007 (20070814/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 2 L3

=> d l4 ibib abs tot

L4 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:638873 HCAPLUS
DOCUMENT NUMBER: 143:153276
TITLE: Preparation of substituted heterocycles, particularly ureidothiophenes, as CHK1 kinase inhibitors for treating neoplasm
INVENTOR(S): Ashwell, Susan; Gero, Thomas; Ioannidis, Stephanos; Janetka, James; Lyne, Paul; Su, Mei; Toader, Dorin; Yu, Dingwei; Yu, Yan
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005066163	A2	20050721	WO 2004-GB5400	20041224
WO 2005066163	A3	20050901		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004312193	A1	20050721	AU 2004-312193	20041224
CA 2552050	A1	20050721	CA 2004-2552050	20041224
EP 1732920	A2	20061220	EP 2004-806196	20041224
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				

CN 1922172	A	20070228	CN 2004-80042170		20041224
BR 2004018351	A	20070508	BR 2004-18351		20041224
JP 2007517843	T	20070705	JP 2006-548370		20041224
US 2007010556	A1	20070111	US 2006-596930		20060629
NO 2006003449	A	20060727	NO 2006-3449		20060726
IN 2006MN00910	A	20070413	IN 2006-MN910		20060731
PRIORITY APPLN. INFO.:			US 2004-534310P	P	20040105
			US 2004-553305P	P	20040315
			WO 2004-GB5400	W	20041224

OTHER SOURCE(S): MARPAT 143:153276
GI



I



II

AB Title compds. I [wherein X = NH, S, O; Y = CH, N; R1 = CN, (un)substituted alk(en)yl, alkoxy, aryl, etc.; R2, R3 = independently CONH2 and derivs., SO2NH2 and derivs., NHCONHR4; R4 = H, OH, benzyl, etc.; and their pharmaceutically acceptable salts; provided that when X = S; Y = CH; R2 = CONH2 and derivs.; and R3 = NHCONHR4; then R1 cannot be hydroxyphenyl or alkoxyphenyl; with the exception of certain compds.] were prepared as checkpoint kinase 1 inhibitors for treating cancer. For example, a 7-step synthesis of ureidothiophene salt II•HCl, starting from phenylacetaldehyde and cyanomethyl acetate, is given. I had IC50 or EC50 ≤ 100 μM in one or both, checkpoint kinase 1 and abrogation assays.

L4 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2005:158658 HCAPLUS
DOCUMENT NUMBER:	142:261391
TITLE:	Preparation of thiophene compounds as CHK1 inhibitors
INVENTOR(S):	Ashwell, Susan; Gero, Thomas; Ioannidis, Stophanos; Janetka, James; Lyne, Paul; Oza, Vibha; Springer, Stephanie; Su, Mei; Yu, Dingwei
PATENT ASSIGNEE(S):	Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE:	PCT Int. Appl., 97 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005016909	A1	20050224	WO 2004-GB3473		20040812
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004265140	A1	20050224	AU 2004-265140		20040812
CA 2535652	A1	20050224	CA 2004-2535652		20040812
EP 1660474	A1	20060531	EP 2004-768043		20040812
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004013585	A	20061017	BR 2004-13585		20040812
CN 1867557	A	20061122	CN 2004-80030364		20040812
JP 2007502308	T	20070208	JP 2006-523673		20040812
NO 2006000718	A	20060301	NO 2006-718		20060214
US 2006281666	A1	20061214	US 2006-568380		20060214
MX 2006PA01775	A	20060517	MX 2006-PA1775		20060215
PRIORITY APPLN. INFO.:			US 2003-495580P	P	20030815
			US 2004-576416P	P	20040528
			WO 2004-GB3473	W	20040812

OTHER SOURCE(S): CASREACT 142:261391; MARPAT 142:261391

GI



I



II

AB Title compds. I [R1, R2 = H, (un)substituted alkyl, (un)substituted heterocyclyl; with proviso that R1 and R2 are not both H; or R1 and R2 and the N to which they are attached in combination form an optionally substituted heterocyclyl; R4 = H, OH, (un)substituted carbocyclyl, etc.; R5 = H, (un)substituted carbocyclyl, (un)substituted alkyl] and their pharmaceutically acceptable salts were prepared For example, amidation of compound II with (CH3)2Al-3-BOC-(S)-3-aminopiperidine, e.g., in-situ prepared by reaction of (S)-3-aminopiperidine-1-carboxylic acid tert-Bu ester with (CH3)3Al, followed by acidic deprotection afforded compound I [NR1R2 = (S)-piperidin-3-ylamino; R4 = H; OR5 = 4-MeO]·HCl in 57% overall yield. In CHK 1 (checkpoint kinase 1) inhibition assays, the IC50 value of compound I [NR1R2 = piperidin-3-ylamino; R4 = H; OR5 = 4-Et2NCH2CH2O]·CF3CO2H was 10 nM. Compds. I are claimed useful for the treatment of cancer, infection.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.86	183.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

STN INTERNATIONAL LOGOFF AT 09:24:11 ON 15 AUG 2007